Eli Lilly and Co. (NYSE:LLY) on Friday shared new results from Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis.

Ebglyss showed sustained similar levels of skin clearance when administered as a single injection of 250 mg once every eight weeks (Q8W) compared with once every four weeks (Q4W).

The data support a potential additional, less frequent maintenance dosing option for more individualized treatment.

Also Read: Eli Lilly’s Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs

Data

These data support that once every eight-week Ebglyss dosing could give a new treatment option using the lowest effective dose.

In the ADjoin extension study, results indicate that maintenance dosing every other month demonstrated similarly high rates of disease control compared to monthly dosing:

79% of patients taking Ebglyss once every other month and 86% of patients taking EBGLYSS monthly, respectively, ...